Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Burlington, VT
NPI: 1255575726Primary Practice Location
University of Vermont Medical Center Inc
111 Colchester Ave, Burlington, VT
Primary Employer
Uvm Medical Center
uvmhealth.org
HQ Phone
Get M.D. Alissa's Phone Numberphone_androidMobile
Get M.D. Alissa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardVT State Medical License
The Warren Alpert Medical School of Brown University
medical.brown.edu
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 63 | 137 |
| 2 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 46 | 110 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 45 | 63 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 35 | 36 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 12 | 16 |
Authors: Thomas, Alissa A, Preston, Julie, Scott, Rod C, Bujarski, Krzysztof A
Journal: Epilepsy Behav
Publication Date: 2013-09-08
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Veliparib, OTHER: Placebo Administration
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Temozolomide, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging, DEVICE: NovoTTF-100A Device
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: Genentech, Inc., National Cancer Institute (NCI), GlaxoSmithKline, Brain Science Foundation
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Vismodegib, DRUG: Capivasertib, DRUG: FAK Inhibitor GSK2256098
